758. Hepatitis B Virus Infection: Evaluating the Impact of Universal Infant Vaccination - US-affiliated Pacific Islands, 1985–2015
Session: Poster Abstract Session: Vaccines: Pediatric
Thursday, October 27, 2016
Room: Poster Hall
Background:  The US-affiliated Pacific Island countries (USAPI) are disproportionately burdened by hepatitis B virus (HBV) infection. To address this, the USAPI introduced universal infant hepatitis B vaccination in the mid-1980s. To evaluate progress toward eliminating HBV infection, we assessed the prevalence of current HBV infection and vaccination coverage among children aged ≤11 years in the USAPI born in the 1980s, 1990s, and 2000s.

Methods:  We obtained demographic and serologic data from serial cross-sectional seroprevalence surveys from convenience samples of children aged 2–11 years recruited in 6 USAPI countries in 1985, 1986, 1991, 1995, 2000, 2005, 2010, 2011, and 2015. Positive hepatitis B surface antigen serologic results were classified as current HBV infections. Vaccination status was determined by vaccination record. Participants who received at least a birth dose of hepatitis B vaccine were considered vaccinated. Descriptive statisticsand a one-way analysis of variance were performed to estimate prevalence of current HBV infection and vaccination coverage for children on the basis of birth year and significant differences in these estimates.

Results: Data were obtained from 4,462 children; 1,323 children (mean age: 7.8 years) born in the 1980s; 362 children (mean age: 4.8 years) born in the 1990s; and 3,142 children (mean age: 6.7 years) born in the 2000s. Of all children, 53.3% were female. Prevalence of current HBV infection significantly decreased (8.4% [1980s]; 2.5% [1990s]; 0.2% [2000s]; P < .0001) as vaccination rates significantly increased (76.4% [1980s]; 87.3% [1990s]; 97.5% [2000s]; P < .0001).

Conclusion:  In an endemic region of the United States, high vaccine coverage corresponded with a significant decrease in the prevalence of current HBV infection over time. With continued universal HBV vaccination, HBV elimination in the USAPI is an achievable goal.

Winston Abara, MD, PhD, Melissa Collier, MD, MPH and Eyasu H. Teshale, MD, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA

Disclosures:

W. Abara, None

M. Collier, None

E. H. Teshale, None

See more of: Vaccines: Pediatric
See more of: Poster Abstract Session

Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.